Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
1 hedge funds and large institutions have $314K invested in Peak Bio, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 8 closing their positions.
88% less capital invested
Capital invested by funds: $2.53M → $314K (-$2.22M)
89% less funds holding
Funds holding: 9 → 1 (-8)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$214K |
| 2 |
Charles Schwab
San Francisco,
California
|
-$162K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$60.3K |
| 4 |
Goldman Sachs
New York
|
-$57.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAI
1
Palo Alto Investors
Palo Alto,
California
| $314K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| – | -$214K | -51,092 | Closed |
|
|
3
Charles Schwab
San Francisco,
California
| – | -$162K | -38,631 | Closed |
|
|
4
Northern Trust
Chicago,
Illinois
| – | -$60.3K | -14,382 | Closed |
|
|
5
Goldman Sachs
New York
| – | -$57.5K | -13,716 | Closed |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| – | -$14K | -3,161 | Closed |
|
7
UBS Group
Zurich,
Switzerland
| – | -$3.01K | -719 | Closed |
|
8
Morgan Stanley
New York
| – | -$1.17K | -278 | Closed |
|
9
Wells Fargo
San Francisco,
California
| – | -$205 | -49 | Closed |
|
PKBO Hedge Fund Activity: Q1 2023 in Review
1 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q1 2023, worth a combined $314K — down 88% from $2.53M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PKBO and 0 opened new positions — a net loss of 8 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Geode Capital Management, exiting entirely with an estimated $214K sold.
- 1 institutional investor held Peak Bio, Inc. Common Stock (PKBO) as of Q1 2023, down from 9 in Q4 2022.
- Funds reported $314K of Peak Bio, Inc. Common Stock stock for Q1 2023, down 88% quarter-over-quarter.
- 0 funds opened new Peak Bio, Inc. Common Stock positions in Q1 2023 and 8 closed out, a net change of -8 holders.
- The largest Peak Bio, Inc. Common Stock seller in Q1 2023 was Geode Capital Management, an estimated $214K sold.
Based on aggregated 13F filings for Q1 2023.